Biocytogen Pharmaceuticals (Beijing) Co (FRA:I54) Total Liabilities : €206.8 Mil (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities?

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the quarter that ended in Dec. 2024 was €206.8 Mil.

Biocytogen Pharmaceuticals (Beijing) Co's quarterly Total Liabilities increased from Dec. 2023 (€213.06 Mil) to Jun. 2024 (€216.15 Mil) but then declined from Jun. 2024 (€216.15 Mil) to Dec. 2024 (€206.82 Mil).

Biocytogen Pharmaceuticals (Beijing) Co's annual Total Liabilities declined from Dec. 2022 (€223.28 Mil) to Dec. 2023 (€213.06 Mil) and declined from Dec. 2023 (€213.06 Mil) to Dec. 2024 (€206.82 Mil).

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Historical Data

The historical data trend for Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Chart

Biocytogen Pharmaceuticals (Beijing) Co Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Total Liabilities

109.14

146.01

223.28

213.06

206.82

Biocytogen Pharmaceuticals (Beijing) Co Semi-Annual Data
	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Liabilities	Get a 7-Day Free Trial				223.28	225.92	213.06	216.15	206.82

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the fiscal year that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	70.164	+	(45.159	+	11.136
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	80.356)
	=	206.8

Total Liabilities	=	Total Assets (A: Dec. 2024 )	-	Total Equity (A: Dec. 2024 )
	=	316.814	-	109.998
	=	206.8

Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	70.164	+	(45.159	+	11.136
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	80.356)
	=	206.8

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	316.814	-	109.998
	=	206.8

Biocytogen Pharmaceuticals (Beijing) Co Total Liabilities Related Terms

Thank you for viewing the detailed overview of Biocytogen Pharmaceuticals (Beijing) Co's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Biocytogen Pharmaceuticals (Beijing) Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocytogen Pharmaceuticals (Beijing) Co Ltd (FRA:I54) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

02315:Hong Kong

Address

12 Baoshen South Street, Daxing Bio-Medicine Industry Park, Daxing District, Beijing, CHN

Website

https://www.biocytogen.com.cn

Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other advanced solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.

Biocytogen Pharmaceuticals (Beijing) Co Headlines

No Headlines